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Abstract
No single gold standard of comorbidity measure has been identified, and the performance of comorbidity
indices vary according to the outcome of interest. The authors compared the Charlson Comorbidity Index,
Elixhauser Index (EI), Chronic Disease Score (CDS), and Health-related Quality of Life Comorbidity Index
(HRQL-CI) in predicting health care-related behaviors (physicians’ concordance with diabetes care standards
and patients’ oral antidiabetic drug [OAD] adherence) and outcomes (health care utilization and expenditures)
among Medicaid enrollees with type 2 diabetes. A total of 9832 diabetes patients who used OAD were iden-
tified using data from the MarketScan Medicaid database from 2003 to 2007. Predictive performance of the
comorbidity index was assessed using multiple regression models controlling for patient demographics, di-
abetes severity, and baseline health care characteristics. Among the 4 indices, the CDS was best at predicting
physician’s concordance with care standards. The CDS and HRQL-CI mental index performed better than
other indices as predictors of medication adherence. The EI was best at predicting health care utilization and
expenditures. These results suggest that, for these low-income diabetes patients, the CDS and HRQL-CI
mental index were relatively better risk-adjustment tools for health care-related behavior data evaluation and
the EI was the first choice for health care utilization and expenditures data. (Population Health Management
2012;15:220–229)
Introduction
Acomorbidity measurement is a tool for quantifyingthe burden of coexisting medical conditions that are
distinct from the primary condition under investigation.1
Accurately measuring comorbidity is essential to the validity
of the findings in epidemiological and health services re-
search. Assessing comparative predictive abilities of co-
morbidity indices is critical because no single gold standard
has been identified, and the predictive performance of a co-
morbidity index varies according to the outcome and popu-
lation of interest.2,3 Hence, the selection of comorbidity index
in studies that require clinical risk adjustment should be
specific to the outcome of interest, population, and source
data. However, in most research, the choice of a comorbidity
index often is based on the convenience of the data source for
measuring comorbidities or simply on the most convenient
method of measurement, rather than considering the relative
performance of alternative comorbidity indices for a given
outcome. Also, most studies that focus on the comparative
performance of comorbidity indices were conducted for only
1 outcome (ie, mortality,4–11 health care utilization,12,13 costs14).
Health care-related behaviors, such as whether the physician’s
treatment is concordant with care standards or a patient’s
medication-taking behaviors, have seldom been used to com-
pare various indices.
The Charlson Comorbidity Index (CCI),15 Elixhauser Index
(EI),16 and Chronic Disease Score (CDS)17 are 3 commonly
used comorbidity indices. The CCI and EI are diagnosis-
derived measures and often are used by investigators
focusing on mortality or health care utilization outcomes.18–20
The CDS is based on the patient’s medications and has
demonstrated better predictive ability in analyses of health
care expenditures when compared to diagnoses-derived
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indices.21,22 The Health-related Quality of Life Comorbidity
Index (HRQL-CI) is a more recently developed, diagnosis-
derived measure originally designed to predict HRQL as
measured by the Short Form-12 using the Medical Ex-
penditure Panel Survey database.23 The HRQL-CI has been
demonstrated to outperform CCI in predicting HRQL out-
come in a general population and an asthma subsample.23
Further research is needed to compare the HRQL-CI with
other existing indices, other types of populations, and using
other types of data sources to assess its performance for other
types of health care outcomes. To date, no study has com-
pared the CCI, EI, CDS, and HRQL-CI directly and compre-
hensively across different health care outcomes.
Medicaid plans cover lower income, ethnically diverse
populations in the United States, and have higher percent-
ages of participants with multiple and severe chronic medi-
cal conditions than commercial plans.24 In terms of chronic
disease, diabetes prevalence is almost twice as high among
Medicaid beneficiaries compared to the general population.25
Medicaid beneficiaries with diabetes tend to be older or
disabled and typically have comorbid conditions that com-
plicate their management. Coexisting medical conditions
contribute to high costs and service use rates for these pa-
tients.26 Therefore, accurately capturing comorbidity burden
in this population is critical to identify populations that need
improvements in care quality or access, and those that use
resources disproportionately. However, there has been little
research comparing the performance of comorbidity mea-
sures in this population.
The present study aimed to compare the predictive per-
formance of commonly used comorbidity indices across
different critical outcomes and to identify the most predictive
measure specific to each outcome for Medicaid patients with
diabetes.
Methods
Data source and study cohort
This observational cohort study used data extracted ret-
rospectively from the Thomson’s MarketScan Medicaid da-
tabase from 2003 to 2007.27 This database contained the
medical, surgical, and prescription drug experiences of
nearly 22 million Medicaid enrollees from 8 de-identified and
geographically dispersed states across the United States.
Although the states were de-identified, the data included at
least 1 state from each US region. It included records of in-
patient services, inpatient admissions, outpatient services,
and prescription drug claims, as well as information on long-
term care and other medical care. In addition to standard
demographic variables such as age and sex, the database
included variables of particular value to researchers who
investigate Medicaid populations such as aid category
(blind/disabled, Medicare eligible), race, service use, and
provider type.27
We defined the years 2004 to 2006 as the index drug
identification period; within these 2 years, the index date was
identified as the date of the first oral antidiabetic drug
(OAD) claim. The pre period and post period included the
time periods 1 year before and 1 year after the index date,
respectively.
Patients included in the analytic cohort met the following
criteria: (1) A diagnosis of type 2 diabetes (International
Classification of Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] = 250.0x-250.9x). (2) Age 18 to 64 years. In-
dividuals age 65 years and older were excluded because they
are likely to be dual-eligible beneficiaries (Medicare and
Medicaid) with Medicare utilization events not captured in
the Medicaid files. (3) Continuous Medicaid enrollment for
12 months before and 12 months after the index date. (4) At
least 1 filled prescription for OAD during the index period.
(5) No OAD prescription in the pre-index period. New OAD
users were targeted because patients on long-term therapy
likely have different service use patterns. (6) Continuous
medication therapy with the OAD index drug in the post-
index period. Continuous therapy was defined as no gap in
refilling of 60 or more days, and at least 2 prescriptions of the
index OAD.
Study variables
As guided by Andersen’s Behavioral Model of Health
Services Use,28 3 types of covariates were included as pre-
dictors for health care outcomes, representing predisposing,
enabling, and need factors in determining service use and
treatment quality. Predisposing characteristics were patient’s
age, sex, and race/ethnicity; enabling characteristics in-
cluded the type of health plan, type of provider (general
practitioner vs. endocrinologist), and the number of thera-
peutic classes and number of medications prescribed; need
factors were diabetes disease severity and comorbidity.
Diabetes severity was defined using 3 common diabetes-re-
lated complications as indicators: nephropathy, neuropathy,
and retinopathy. The presence of each complication was re-
corded as a dichotomous variable. All predictors were
measured in the pre-index period. Measurements of co-
morbidity and health care-related outcomes of interest (ie,
physician concordance with diabetes care standards, patient
OAD medication adherence, health care utilization, costs) are
specified in the following sections. All outcomes were mea-
sured in the post-index period.
Comorbidity index scores
Four types of comorbidity index scores were constructed:
CCI, EI, CDS, and HRQL-CI. We used a modified version of
the Romano-adapted CCI for use with administrative data29;
this comprises 17 disease items weighted according to dis-
ease severity as 1, 2, 3, or 6. Severity weights are based on the
adjusted relative risks of death from the Cox proportional
hazard regression model used in the original development of
the index.30 The final CCI score is the sum of weights as-
signed to all of a patient’s comorbidities. The EI is originally
measured as 30 dichotomous variables, each representing
one of the comorbidity groups.16 It has been condensed to a
single numeric score that summarizes disease burden and is
adequately discriminative for death in hospital when ana-
lyzing administrative data.31 We used this condensed single
EI score for comparison to other single index scores such as
the CCI. The RxRisk 32 is a revised and expanded version of
the original CDS.17 For adults, the RxRisk identifies 25
distinct comorbid conditions by linking them to medica-
tions used during treatment. Weights for the RxRisk will be
taken directly from originally published prospective cost
coefficient estimates.33 The HRQL-CI consists of 2 lists: 20
physical and 15 clinical conditions for mental aspects of
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illness burden. Each condition is assigned a point weight
based on its relative influence on the HRQL outcomes
(Short Form-12 Physical Component Score or Mental
Component Score).23 The final HRQL-CI physical or mental
index score is the sum of weights assigned to each condition
presented by the patient. The scores derived from the CCI,
EI, and HRQL-CI indices were based on a list of selected
ICD-9-CM diagnosis codes from inpatient and outpatient
claims, while the CDS was estimated utilizing selected
National Drug Code numbers from pharmacy prescription
claims. We excluded the diagnostic codes of type 2 diabe-
tes because of the disease population studied. The time
period for constructing comorbidity score was the pre-
index period.
Physician concordance with diabetes care standards
The American Diabetes Association recommends that each
of the following services be performed for adults with type 2
diabetes34: semiannual hemoglobin (HbA1c) testing, and
annual cholesterol tests, eye examinations, and mircoalbu-
minuria tests to detect kidney disease. These performance
measures also have been used to evaluate the quality of di-
abetes care.35,36 Researchers have evaluated the relationship
between the comorbidity burden, measured using such tools
as the CCI,37 and the quality of diabetes care,37–39 and found
that patients with a higher comorbidity burden received
better care. In the current study, a summary measure was
calculated representing the number of measures performed
as recommended. A person who received more than 2
HbA1c tests during the year was given credit for only 1.
Similarly, a person who received more than the re-
commended number of cholesterol tests, eye exams, or mi-
croalbumin tests was given credit for only the recommended
number of tests. The summary score ranged from 0 to 4
standard concordant areas of care.
Patient medication adherence
Medication adherence focused on 3 common OADs as
index drugs, including sulfonylureas, metformin, and thia-
zolidinediones and their fixed-dose regimens: Glucovance
(glyburide plus metformin), Avplusamet (rosiglitazone plus
metformin), Metaglip (glipizide plus metformin), and Ac-
taoplusMet (pioglitazone plus metformin). Adherence was
measured using medication possession ratio (MPR),40 a
common measure calculated based on administrative claims
for medication fills.41 The MPR is defined as the proportion
of days within an observation period for which a specific
drug or class of drugs is supplied. In this study, the time
window for measuring adherence began with the first date of
OAD dispensing (index date) and ended with the dispensing
date of the last prescription within the post-index period. The
formulas for computing the MPR for each OAD drug or
regimen were as follows.
For monotherapy or fixed-dose regimen: MPR = total days
supply obtained/(date of the last claim - date of the first
claim + days supply of the last claim);
For combination therapy (eg, using more than 1 type of
index drug or switching drugs): MPR = total days supply
obtained/n*(date of the last claim - date of the first
claim + days supply of the last claim)
(n = no. of OAD combined, [eg, for dual therapy, n = 2])
If the MPR exceeded 1.0 (indicating overstocking) it was
truncated at 1.0.
Using standard conventions, we classified patients with an
MPR of less than 0.8 (eg, less than 80% adherent) as non-
adherent.42 This threshold has been used in previous studies
of OAD adherence among Medicaid beneficiaries and found
to discriminate well in terms of patients’ medication-taking
behaviors.43
Health care utilization and costs
Health care utilization included total number of hospi-
talizations, emergency room (ER) visits, and outpatient vis-
its. Health care costs included total costs and diabetes care-
related costs in the post-index period. Total cost was the sum
of the costs submitted from both inpatient and outpatient
claims files. Diabetes-related cost was the sum of all medical
claims with a primary diagnosis of type 2 diabetes
Statistics
Descriptive statistics of population characteristics were
calculated, including means, standard deviations, and
proportions as appropriate. The correlations between co-
morbidity indices were assessed using Spearman rank cor-
relations.
Predictive ability of comorbidity indices for health care
outcomes was assessed using multiple regression techniques
controlling for patient demographics, type of health plan,
type of provider, number of therapeutic classes, and number
of medications prescribed, diabetes disease severity, and
baseline health care-related characteristics (eg, health care
costs in the pre-index period). Specific regression analyses
were chosen based on the property of each outcome. Scores
of physician concordance with diabetes care standards, a
count variable, was modeled using standard Poisson re-
gression. We modeled medication adherence as a dichoto-
mous variable based on an MPR value of 0.8 (MPR ‡ 0.8 =
adherent; MPR < 0.8 = not adherent) and applied logistic
regression analysis. Zero-inflated binomial regression anal-
ysis was applied for each type of health care utilization
data. Medical expenditures data were skewed consider-
ably to right. To deal with skewed data, a generalized lin-
ear model with gamma family and log link function was
used.44
The likelihood ratio for goodness of fit, deviance, and
adjusted R2 were reported as statistical evidence of model fit,
compared to the nested intercept only model. The deviance is
the value that compares a given model to a fully saturated
one so that it reflects error associated with the model even
after the predictors are included in the model. The smaller
the deviance, the better the model fits the data. Two common
information criterion measures, the Akaike’s information
criterion (AIC) and Bayesian information criterion (BIC),45
were used to compare non-nested models; the model with
the smallest AIC or BIC value was the best model.46 The AIC
difference (DAIC) was then calculated following Anderson
and Burnham’s method to select the best approximating
model.47 The DAIC is the difference between the AIC and the
minimum of AIC over all candidate models, which provides
a quantitative measure of model plausibility. A zero differ-
ence between 2 models indicates the best model, models
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Table 1. Characteristics of Study Population (n = 9832)
Type Variables Mean (S.D.) Frequency (%)
Predisposing
(pre-index period)
Age (years) 44.81 (11.64) –













Index Score (range: 0–35)
0.709 (1.27) –
Elixhauser Index Score (range: 0–30) 1.73 (1.55) –
Chronic Disease Scores (range: 0–18) 4.64 (2.96) –
HRQL-CI Scores –
Physical domain (range: 0–35) 4.15 (3.69)
Mental domain (range: 0–25) 3.65 (3.39)
Enabling
(pre-index period)
Type of health plan –
Fee-for-service 5448 (55.41)
Capitated plan 3203 (32.58)
Both 1181 (12.01)
Type of provider: at least 1
endocrinologist visit (yes/no)
– 31 (0.32)
Total no. of therapeutic classes 10.82 (10.82) –




At least 2 HbA1c tests/year 6950 (70.69)
At least 1 LDL test/year 6209 (63.15)
At least 1 nephropathy screening/year 2326 (23.66)
At least 1 eye examination/year 4297 (43.70)
Total physician treatment adherence





Overall adherence (MPR) for 3 selected
OADs (Met, Sulfa, TZD) (n = 9832)
0.81 (0.26) –
MPR for monotherapy (n = 7888) 0.78 (0.23)
Met (n = 62) 0.70 (0.21)
Sulfa (n = 5949) 0.77 (0.24)
TZD (n = 1877) 0.81 (0.21)
MPR for fixed dose regimensa (n = 290) 0.78 (0.21)
MPR for switching or combination
regimens (n = 1645)
0.95 (0.12)
Health care utilization
Total no. of hospital admissions
Pre-index period 0.38 (0.09)
Post-index period 0.35 (0.096)
Total no. of emergency room visits
Pre-index period 0.23 (0.09)
Post-index period 0.21 (0.74)
Total no. of outpatient visits
Pre-index period 24.47 (14.85)
Post-index period 27.43 (17.45)
Health care costs
Total costs ($)
Pre-index period 8318.34 (24,051)
Post-index period 8807.67 (27,204)
Diabetes care-related costs ($)
Pre-index period 1282.93 (8381)
Post-index period: 2257.99 (9968)
HRQL-CI, Health-related Quality of Life Comorbidity Index; LDL, low-density lipoprotein; Met, metformin; MPR, medication possession
ratio; OAD, oral antidiabetic medication; Sulfa, sulfonylurea; TZD, thiazolidinediones; a:4 fixed-dose regimens are Glucovance, Avplusamet,
Metaglip, and Actaoplus Met.
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having DAIC < 2–3 are nearly tied, models having DAIC be-
tween 7 and 10 are considered fair, and models having
DAIC > 7 to 10 are substantially inferior.47
Data management was conducted using SAS software
version 9.1 (SAS Institute Inc., Cary, NC) and then data were
converted into STATA software (StataCorp LP, College Sta-
tion, TX) format for the analyses. This study protocol was
approved by the University of Michigan Health Sciences and
Behavioral Sciences Institutional Review Board.
Results
Characteristics of study population
The study population characteristics are displayed in
Table 1.
The study population of 9,832 patients was on average
44.81 years (SD, 11.64). The majority was female (73%),
White (52%), on the fee-for-service plan (55%), and with
average 11 (SD, 10.82) different types of therapeutic classes
and average 557 (SD, 48.64) drugs prescribed during the
pre-index period. Two percent of individuals were diag-
nosed with nephropathy, 5% of individuals with neuropathy
and 2% of individuals with retinopathy.
Over half of the population had HbA1c tests at the re-
commended frequency. More than half had the re-
commended one LDL-c test and one eye examination per
year. Less than one quarter of the population had at least one
nephropathy screening per year. The average score for
physician’s concordance with care standards was 2.51 (SD,
1.11). The average MPR was 0.81 (SD, 0.26). The average
MPR for patients having switching or combination regimens
was higher than patients on monotherapy or fixed-dose re-
gimens. Within patients on monotherapy, those treated by
thiazolidinediones had highest average MPR scores.











Charlson Comorbidity Index 1.00
Elixhauser Index 0.56 1.00
HRQL-CI-Physical Aspect 0.55 0.65 1.00
HRQL-CI-Mental Aspect 0.39 0.59 0.68 1.00
Chronic Disease Score 0.41 0.59 0.60 0.52 1.00
HRQL-CI, Health-related Quality of Life Comorbidity Index; All correlations between any 2 different indices were statistically significant
( P < 0.0001).
Table 3. Predictive Validity of Comorbidity Indices in Health Care-Related Behaviors
Response Variable: Physician Concordance with Care Standard
Predictor of interest
Goodness of Fit for overall modela For 1-unit increase in
comorbidity score, % change





Adjusted R2 AIC BIC
CCI 202.81 32031.18 0.14 32075.18 32233.41 - 0.2, p = 0.644
EI 210.96 32023.03 0.15 32067.03 32225.27 1.4, p = 0.000
CDS 219.71 32014.28 0.15 32058.28 32216.52 1.7, p = 0.000
HRQL-CI–physical 209.70 32024.29 0.15 32068.29 32226.53 0.6, p = 0.00
HRQL-CI–mental 205.23 32028.73 0.14 32072.73 32230.97 0.4, p = 0.015
Response Variable: Patient Oral Antidiabetic Medication Adherence
Predictor of interest
Goodness of Fit for overall modela For 1-unit increase in
comorbidity score, % change
in the odds of being
medication adherentd
Likelihood
ratiob Deviance Max-rescaled R2 AIC BIC
CCI 495.94 12394.62 0.17 12430.62 12560.08 0.6, p = 0.7596
EI 496.77 12393.79 0.17 12429.79 12559.25 1.7, p = 0.3366
CDS 502.95 12387.61 0.17 12423.61 12553.08 3.7, p = 0.0078
HRQL-CI–physical 496.23 12394.32 0.17 12430.32 12559.79 - 0.5, p = 0.5335
HRQL-CI–mental 506.16 12384.40 0.19 12420.40 12549.87 - 2.5, p = 0.0013
AIC, Akaike’s information criterion; BIC, Bayesian information criterion; CCI, Charlson Comorbidity Index; EI, Elixhauser Index; CDS,
Chronic Disease Score; HRQL-CI, Health-related Quality of Life Comorbidity Index. aThe variables included in the model were comorbidity
score, patient’s age, race, sex, type of health plan, type of provider, number of therapeutic classes and number of medications prescribed,
diabetes disease severity, and baseline health care-related characteristics (eg, health care costs in pre-index period). b X2 test for the likelihood
ratio for each individual model was statistically significant ( P = 0.000). c The analysis is based on standard Poisson regression, the value in the
column was calculated as: 100*b%, where b = beta-coefficient. dThe analysis based on logistic regression, the value in the column was
computed by the formula: 100*[exp]c-1]%, where exp(c) = exponentiated coefficient.
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The average of health care utilization per year in pre-index
period was generally higher than in post-index period across
different types of health care services. However, the average
of medical costs or diabetes care-related costs per year in the
post-index period was higher than in the pre-index period.
Correlations between comorbidity indices
The correlations between any 2 of the diagnosis-based
indices (ie, CCI, EI, HRQL-CI) were fair (P > 0.5), with the
exception of a small correlation between the CCI and
HRQL-CI mental index (Table 2). Also, there were fair
correlations between any 1 of the diagnosis-based indices
and medication-based index (CDS), with the exception of a
slightly low correlation between the CCI and CDS.
Predictive performance of comorbidity index
When predicting physician concordance with diabetes
care standards, the model with CDS comorbidity scores had
the best fit (smallest deviance, AIC and BIC values, and
higher adjusted R2) (Table 3). In predicting patient’s medi-
cation adherence, the HRQL-CI mental index-based model
had the best fit (smallest deviance, AIC and BIC values,
higher R2). The difference in the AIC (DAIC) between the
HRQL-CI mental index- and CDS-based models was close to
3, indicating that these 2 index-based models were tied (2
approximating models, in terms of model fit). However, the
DAIC between the HRQL-CI mental index and CCI, EI, or
HRQL-CI physical index-based model was over 7, implying
that the fit in the models with other comorbidity index scores
were substantially inferior compared with the HRQL-CI
mental index-based model.
Comorbidity scores measured by the CDS or HRQL-CI-
mental index were statistically significantly associated with
medication adherence. However, these indices indicated
different directions of comorbidity impact.
When predicting hospitalization and ER visits, the models
with diagnosis-based comorbidity index scores (CCI and EI)
Table 4. Predictive Performance of Comorbidity Index in Health Care Utilization
Response Variable: Number of Hospitalizations
Predictor of interest
Goodness of Fit for overall modela
For 1-unit increase in






CCI 1122.29 13604.65 0.07 13706.65 14073.48 10.22***
EI 1120.30 13606.64 0.07 13708.64 14075.46 10.23***
CDS 1110.06 13616.87 0.07 13718.87 14085.70 6.67***
HRQL-CI–physical 1104.80 13622.14 0.07 13724.14 14090.97 3.21***
HRQL-CI–mental 1111.11 13615.82 0.07 13717.82 14084.65 3.83***
Response Variable: Number of Emergency Room (ER) Visits
Predictor of interest
Goodness of Fit for overall model a
For 1-unit increase in
comorbidity score,





CCI 1075.97 9394.46 0.09 9496.46 9863.29 9.2***
EI 1074.87 9395.57 0.09 9497.57 9864.39 9.5***
CDS 1072.65 9397.78 0.09 9499.784 9866.61 7.4***
HRQL-CI–physical 1067.27 9421.12 0.09 9505.17 9872.0 3.2***
HRQL-CI–mental 1072.03 9398.41 0.09 9500.41 9867.232 4.0***
Response Variable: Number of Outpatient Visits
Predictor of interest
Goodness of Fit for overall modela
For 1-unit increase in






CCI 8117.51 76861.95 0.09 76961.95 77321.58 6.6***
EI 8298.86 76680.59 0.10 76780.59 77140.22 9.8***
CDS 8131.51 76847.94 0.09 76935.94 77252.42 5.2***
HRQL-CI–physical 8245.29 76734.17 0.10 76836.17 77202.99 3.9***
HRQL-CI–mental 8438.71 76540.74 0.10 76640.74 77000.37 5.3***
AIC, Akaike’s information criterion; BIC, Bayesian information criterion; CCI, Charlson Comorbidity Index; EI, Elixhauser Index; CDS,
Chronic Disease Score; HRQL-CI, Health-related Quality of Life Comorbidity Index. a The variables included in the model were comorbidity
score, patient’s age, race, sex, type of health plan, type of provider, number of therapeutic classes and number of medications prescribed,
diabetes disease severity, and baseline health care-related characteristics (eg, health care costs in pre-index period). b X2 test for the likelihood
ratio for each individual model was statistically significant ( P = 0.000). c The analysis is based on zero-inflated negative binomial regression,
the value in the column was calculated as: 100*b%, where b = beta-coefficient; ***P value = 0.000.
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demonstrated better model fit (smaller deviance, AIC and
BIC values), compared to medication-based comorbidity in-
dex scores (CDS) (Table 4). Because the DAIC between the
CCI and EI-based models was close to 3, these 2 models were
tied. However, the DAIC between the CCI (or EI) and CDS-
based models was over 10, implying that the model with a
medication-based comorbidity index score was substantially
inferior to one with diagnosis-based scores. In predicting
outpatient visits, the model with HRQL-CI mental index
scores had the best fit (smallest deviance, AIC and BIC val-
ues, higher R2).
The models with EI comorbidity scores had better overall
fit in predicting health care expenditures (smallest deviance,
AIC and BIC values, higher R2) (Table 5).
Discussion
To our knowledge, this is the first study to evaluate the
comparative predictive performance of the CCI, EI, CDS, and
HRQL-CI indices across different critical outcomes among a
Medicaid-insured sample with chronic diseases. Overall, our
findings showed that the predictive performance of a co-
morbidity index varied depending on the outcome of interest
and, therefore, we suggest that the selection of comorbidity
index should be specific to a given health care outcome (as
summarized in Table 6). Our results also demonstrate the
potential direction and magnitude of comorbidity impact on
health care outcome.
First, when analyzing physician concordance with diabetes
care standards as the outcome, the CDS comorbidity score had
best predictive ability. According to the CDS comorbidity
score, comorbidity positively influenced physicians’ care be-
havior, which supports previous findings that diabetes pa-
tients who have a greater comorbidity burden are more likely
to receive recommended diabetes care.37,38 This may be be-
cause patients with multiple conditions have a greater number
of clinic visits scheduled, have lower no-show rates at sched-
uled appointments, or receive more medication prescription
treatment and greater attention to comprehensive diabetes
management standards during scheduled encounters.
When predicting patients’ medication adherence, the CDS
and HRQL-CI mental index were relatively better co-
morbidity measurements. However, these indices indicated
different directions of comorbidity influence: as the CDS
comorbidity score increased, medication adherence in-
creased; however, as the HRQL-CI mental index score in-
creased, adherence decreased. This difference may be
because the CDS and HRQL-CI mental index measure dif-
ferent underlying dimensions of comorbidity burden. The
CDS index, which is based on a list of medications re-
presenting 30 underlying disease conditions,32,33 attempts to
provide a comprehensive picture of the patient’s overall co-
morbidity burden, while the HRQL-CI mental index origi-
nally was developed to capture the mental aspect of illness
burden.23 Because these 2 indices might represent different
underlying disease profiles, our results suggest that mental
illness burden could have a deterrent effect on medication
adherence, while overall illness burden may enhance pa-
tients’ adherence to treatment. Consistently, previous re-
search that focused on patients with diabetes showed that
the mental aspect of illnesses, particularly depression, had a
negative impact on their OAD adherence.48–50 Research also
has found that increasing overall illness burden was associ-
ated with higher medication adherence.51 It is conceivable
Table 5. Predictive Performance of Comorbidity Index in Health Care Expenditures
Response Variable: Total Medical Costs
Goodness of Fit for overall modela
Predictor of interest Likelihood ratiob Deviance Pseudo-R2 AIC BIC
For 1-unit increase in
comorbidity score,
% change in the costc
CCI 5382.44 18567.38 0.27 19.63 - 71474.98 11.51***
EI 5509.74 18452.98 0.28 19.61 - 71589.37 15.32***
CDS 5374.54 18576.07 0.27 19.63 - 71466.28 8.37***
HRQLCI–physical 5391.14 18562.69 0.27 19.63 - 71479.67 4.99***
HRQL-CI–mental 5498.35 18460.49 0.28 19.61 - 71581.87 6.48***
Response Variable: Diabetes Care-Related Costs
Goodness of Fit for overall modela
Predictor of interest Likelihood ratiob Deviance Pseudo-R2 AIC BIC
For 1-unit increase in
comorbidity score,
% change in the costc
CCI 5515.87 27111.63 0.32 16.89 - 62939.91 14.93***
EI 6235.12 26661.73 0.36 16.82 - 63389.82 28.67***
CDS 5808.91 26924.47 0.34 16.86 - 63127.08 16.12***
HRQL-CI–physical 5989.68 26829.87 0.35 16.84 - 63221.68 9.89***
HRQL-CI–mental 5824.17 26879.12 0.34 16.86 - 63172.42 8.55***
AIC, Akaike’s information criterion; BIC, Bayesian information criterion; CCI, Charlson Comorbidity Index; EI, Elixhauser Index; CDS,
Chronic Disease Score; HRQL-CI, Health-related Quality of Life Comorbidity Index. a The variables included in the model were comorbidity
score, patient’s age, race, sex, type of health plan, type of provider, number of therapeutic classes and number of medications prescribed,
diabetes disease severity, and baseline health care-related characteristics (eg, health care costs in pre-index period). b X2 test for the likelihood
ratio for each individual model was statistically significant ( P = 0.000). c The analysis is based on the Generalized Linear Model with gamma
family and log link, the value in the column was computed by the formula: 100*[exp(c)-1]%, where exp(c) = exponentiated coefficient; ***P
value = 0.000.
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that patients who have a higher number of chronic condi-
tions could be better informed about diabetes and its com-
plications and, therefore, would maintain higher rates of
adherence despite their greater medication burden and nu-
merous comorbidities. Also, increased perceived susceptibility
and severity resulting from comorbid condition burden
may motivate patients to improve their medication-taking
behavior.
Moreover, analyzing health care utilization data in the
context of hospitalization and ER visits, the diagnosis-based
index (ie, EI) had better predictive performance than the
medication-based index (CDS). This confirmed previous re-
search findings, which showed that diagnosis-based co-
morbidity scores had better ability to predict health care
utilization compared to a medication-based index.12 Inter-
estingly, we also found that the mental illness aspect of the
comorbidity index (HRQL-CI mental index) had the best
predictive ability for health care use in the context of out-
patient visits, compared to other comorbidity indices that
measure overall comorbidity burden (ie, EI, CDS). Further
research is needed to validate this finding in other popula-
tions and health care settings.
Furthermore, regarding medical payment data, our findings
support previous research focused on Medicaid enrollees,
which demonstrated that the diagnosis-based index had better
predictive ability than the medication-based index among
Medicaid beneficiaries.52 However, this finding may be spe-
cific to the context of the Medicaid population because some
previous literature demonstrated that the medication-based
index had better performance in predicting health care ex-
penditures (for elderly patients diagnosed with hypertension,53
community dwelling elderly,54 and migraine patients55).
These study findings should be interpreted in light of the
following limitations. First, because the analyses were based
on claims data, information on services not billed to Medicaid
was not available (ie, patients may have received treatment
that was not submitted to their health plan for reimbursement
and thus was not included in the claims data). Health care cost
in our analysis, which was based only on the claim for re-
imbursement, may not reflect actual payments for services,
although our results should show the same trends in general.
Second, correct categorization of insurance database infor-
mation depends on correct coding by clinicians and other
medical staff. The accuracy of diagnostic coding cannot be
evaluated in a claims-based study. When coding each ICD-9-
CM claims-based measurement, the possibility exists that di-
agnoses that were designated to be ruled out for billing pur-
poses were misclassified as existing comorbidities.1 Third,
data on comorbidities were limited to the conditions coded on
medical claims within the time frame studied. Fourth, caution
should be used when generalizing results beyond the study
population of continuously enrolled Medicaid type 2 diabetes
patients aged 18 to 64 who use OAD. Also, our sample was
predominantly female and white.
In conclusion, while more work is warranted to evaluate
whether these findings can be supported in other popula-
tions, these results are nevertheless important for epidemi-
ological and health services researchers in the selection and
use of existing alternative comorbidity indices to assess and
control for comorbidity burden on health care outcomes.
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